IDP Pharma has entered into a licensed option with a USA based Biotech for IDP-602, a first in class drug targeting IDPs driving eye diseases. The company is responsible to develop IDP-602 across preclinical and formulation work prior to executing a license option.
IDP Pharma consolidates its position in cancer while its partners expand applications to other therapeutic areas.
This early stage product was developed thanks to INTRAMETICS platform, a unique technology that allows to design for the first time drugs that target intrinsically disordered transcription factors (IDPs), long quested by pharmaceutical industry with no success.
